Ascendis Pharma to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 07 2024 - 8:30AM
Ascendis Pharma A/S (Nasdaq: ASND) today announced that company
executives will participate in the Oppenheimer 34th Annual
Healthcare Life Sciences Conference.
Details:
Event |
Oppenheimer 34th Annual Healthcare Life Sciences Conference |
Location |
Virtual |
Date |
Tuesday, February 13, 2024 |
Time |
4:00 p.m. Eastern Time / 1:00 p.m. Pacific Time |
A live webcast of the event will be available via the Investors
& News section of the Ascendis Pharma website at
investors.ascendispharma.com. A webcast replay will also be
available on this website shortly after conclusion of the event for
30 days.
About Ascendis Pharma A/SAscendis Pharma is
applying its innovative platform technology to build a leading,
fully integrated biopharma company focused on making a meaningful
difference in patients’ lives. Guided by its core values of
patients, science and passion, the company uses its TransCon
technologies to create new and potentially best-in-class therapies.
Ascendis is headquartered in Copenhagen, Denmark and has additional
facilities in Germany and the United States. Please visit
http://ascendispharma.com to learn more.
Forward-Looking StatementsThis press release
contains forward-looking statements that involve substantial risks
and uncertainties. All statements, other than statements of
historical facts, included in this press release regarding
Ascendis’ future operations, plans and objectives of management are
forward-looking statements. Examples of such statements include,
but are not limited to, statements relating to (i) Ascendis’
ability to apply its innovative platform technology to build a
leading, fully integrated, biopharma company, and (ii) Ascendis’
use of its TransCon technologies to create new and potentially
best-in-class therapies. Ascendis may not actually achieve the
plans, carry out the intentions or meet the expectations or
projections disclosed in the forward-looking statements and you
should not place undue reliance on these forward-looking
statements. Actual results or events could differ materially from
the plans, intentions, expectations and projections disclosed in
the forward-looking statements. Various important factors could
cause actual results or events to differ materially from the
forward-looking statements that Ascendis makes, including the
following: dependence on third party manufacturers, distributors
and service providers for Ascendis’ products and product
candidates; unforeseen safety or efficacy results in Ascendis’
development programs or on-market products; unforeseen expenses
related to commercialization of any approved Ascendis products;
unforeseen expenses related to Ascendis’ development programs;
unforeseen selling, general and administrative expenses, other
research and development expenses and Ascendis’ business generally;
delays in the development of its programs related to manufacturing,
regulatory requirements, speed of patient recruitment or other
unforeseen delays; Ascendis’ ability to obtain additional funding,
if needed, to support its business activities; the impact of
international economic, political, legal, compliance, social and
business factors. For a further description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to Ascendis’ business in general, see Ascendis’ Annual
Report on Form 20-F filed with the U.S. Securities and Exchange
Commission (SEC) on February 16, 2023, and Ascendis’ other future
reports filed with, or submitted to, the SEC. Forward-looking
statements do not reflect the potential impact of any future
licensing, collaborations, acquisitions, mergers, dispositions,
joint ventures, or investments that Ascendis may enter into or
make. Ascendis does not assume any obligation to update any
forward-looking statements, except as required by law.
Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company
logo, and TransCon are trademarks owned by the Ascendis Pharma
group. © February 2024 Ascendis Pharma A/S.
Investor
Contacts: Tim Lee
Ascendis Pharma+1 (650)
374-6343tle@ascendispharma.comir@ascendispharma.com |
|
Media
Contact:Melinda BakerAscendis Pharma+1 (650)
709-8875media@ascendispharma.com |
|
|
|
Patti BankICR Westwicke+1 (415)
513-1284patti.bank@westwicke.com |
|
|
|
|
|
Ascendis Pharma AS (NASDAQ:ASND)
Historical Stock Chart
From Apr 2024 to May 2024
Ascendis Pharma AS (NASDAQ:ASND)
Historical Stock Chart
From May 2023 to May 2024